Tivozanib (AV-951), Inhibitor

Tivozanib (AV-951)

Cat. Num. AAA384260

• Purity: >98%
• Synonyms: Tivozanib (AV-951); AV-951; AV951; inhibitor

• Purity/Purification: >98%
• Form/Format: Powder
• Concentration: 0.1 mM: 21.98 mL (1 mg); 109.91 mL (5 mg); 219.83mL (10 mg); 0.5 mM: 4.4 mL (1 mg); 21.98 mL (5 mg); 43.97 mL (10 mg); 1 mM: 2.2 mL (1 mg); 10.99 mL (5 mg); 21.98 mL (10 mg); 5 mM: 0.44 mL (1 mg); 2.2 mL (5 mg); 4.4 mL (10 mg) (varies by lot)

• CAS Number: 475108-18-0
• Formula: C22H19ClN4O5
• SMILES: CC1=CC(=NO1)NC(=O)NC2=C(C=C(C=C2)OC3=C4C=C(C(=CC4=NC=C3)OC)OC)Cl
• Actions: Inhibitor
• In Vivo Solvent: 0.5% methylcellulose
• Solubility (DMSO): 20 mg/mL (43.96 mM)
• Solubility (Ethanol): <1 mg/mL (<1 mM)
• Solubility (in vivo): 30 mg/mL
• Solubility (Water): <1 mg/mL (<1 mM)
• Availability: We cannot ship this item to Switzerland, Italy, Germany, France and Austria.
• Preparation and Storage: at -20 degree C 3 years Powder

Chemical Structure

Related Product Information for Tivozanib (AV-951), inhibitor

Tivozanib (AV-951) is an oral VEGF receptor tyrosine kinase inhibitor that is designed to inhibit all three VEGF receptors.

References

Majid Momeny, .et al. Anti-tumour activity of tivozanib, a pan-inhibitor of VEGF receptors, in therapy-resistant ovarian carcinoma cells, Sci Rep, 2017, 7: 45954 PMID: 28383032
Majid Momeny, .et al. Blockade of vascular endothelial growth factor receptors by tivozanib has potential anti-tumour effects on human glioblastoma cells, Sci Rep, 2017, 7: 44075 PMID: 28287096
Nicholas A. Manieri, .et al. Mucosally transplanted mesenchymal stem cells stimulate intestinal healing by promoting angiogenesis, J Clin Invest, 2015, Sep 1; 125(9): 3606-3618 PMID: 26280574
Usui T, .et al. Brain-derived neurotrophic factor promotes angiogenic tube formation through generation of oxidative stress in human vascular endothelial cells., Acta Physiol (Oxf), 2014, 211, 385-394 PMID: 24612679